Fifth Third Bancorp Increases Holdings in ANI Pharmaceuticals, Inc. $ANIP

Fifth Third Bancorp raised its holdings in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 17,255.6% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 9,372 shares of the specialty pharmaceutical company’s stock after acquiring an additional 9,318 shares during the quarter. Fifth Third Bancorp’s holdings in ANI Pharmaceuticals were worth $721,000 as of its most recent filing with the SEC.

Other hedge funds have also made changes to their positions in the company. Vanguard Group Inc. lifted its stake in ANI Pharmaceuticals by 2.2% during the fourth quarter. Vanguard Group Inc. now owns 1,305,068 shares of the specialty pharmaceutical company’s stock worth $103,022,000 after purchasing an additional 27,598 shares during the last quarter. State Street Corp increased its stake in ANI Pharmaceuticals by 2.2% in the fourth quarter. State Street Corp now owns 727,204 shares of the specialty pharmaceutical company’s stock valued at $57,405,000 after purchasing an additional 15,496 shares during the last quarter. UBS Group AG increased its stake in ANI Pharmaceuticals by 45.8% in the third quarter. UBS Group AG now owns 589,874 shares of the specialty pharmaceutical company’s stock valued at $54,032,000 after purchasing an additional 185,172 shares during the last quarter. Tang Capital Management LLC raised its holdings in ANI Pharmaceuticals by 51.6% during the fourth quarter. Tang Capital Management LLC now owns 481,437 shares of the specialty pharmaceutical company’s stock worth $38,005,000 after purchasing an additional 163,937 shares in the last quarter. Finally, Geode Capital Management LLC raised its holdings in ANI Pharmaceuticals by 4.2% during the fourth quarter. Geode Capital Management LLC now owns 477,272 shares of the specialty pharmaceutical company’s stock worth $37,682,000 after purchasing an additional 19,258 shares in the last quarter. Hedge funds and other institutional investors own 76.05% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently issued reports on the stock. Guggenheim restated a “buy” rating and issued a $124.00 target price on shares of ANI Pharmaceuticals in a report on Friday, July 10th. Zacks Research cut shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 14th. Weiss Ratings raised shares of ANI Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Tuesday, June 23rd. Wall Street Zen upgraded shares of ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 9th. Finally, Canaccord Genuity Group assumed coverage on ANI Pharmaceuticals in a research report on Thursday, July 16th. They set a “hold” rating and a $91.00 target price on the stock. Six investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $105.00.

ANI Pharmaceuticals Stock Performance

Shares of ANIP opened at $78.37 on Tuesday. The company’s 50 day simple moving average is $81.24 and its 200-day simple moving average is $79.48. The firm has a market cap of $1.78 billion, a PE ratio of 19.84 and a beta of 0.43. ANI Pharmaceuticals, Inc. has a 12-month low of $62.60 and a 12-month high of $99.50. The company has a current ratio of 3.12, a quick ratio of 2.52 and a debt-to-equity ratio of 1.06.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings results on Friday, May 8th. The specialty pharmaceutical company reported $2.05 EPS for the quarter, beating the consensus estimate of $1.28 by $0.77. The firm had revenue of $237.46 million during the quarter, compared to the consensus estimate of $207.63 million. ANI Pharmaceuticals had a net margin of 9.98% and a return on equity of 27.51%. ANI Pharmaceuticals’s revenue for the quarter was up 20.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.70 EPS. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. As a group, equities analysts predict that ANI Pharmaceuticals, Inc. will post 8.03 EPS for the current year.

Insider Buying and Selling

In other news, Director Patrick D. Walsh sold 10,000 shares of the company’s stock in a transaction dated Wednesday, May 13th. The shares were sold at an average price of $80.63, for a total value of $806,300.00. Following the completion of the sale, the director directly owned 38,432 shares of the company’s stock, valued at approximately $3,098,772.16. This represents a 20.65% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Thomas Haughey sold 2,000 shares of the firm’s stock in a transaction dated Monday, June 8th. The stock was sold at an average price of $80.88, for a total value of $161,760.00. Following the transaction, the director directly owned 38,878 shares in the company, valued at approximately $3,144,452.64. This represents a 4.89% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 85,179 shares of company stock valued at $6,722,596 in the last quarter. Corporate insiders own 8.10% of the company’s stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.